Evidence map›Paper›PMID 26998297›Full record

ArticleMolecular and clinical oncology2016

Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group.

Masaharu Inagaki, Yoko Shinohara, Takayuki Kaburagi, Shinsuke Homma, Nobuyuki Hizawa, Hiroyuki Nakamura, Kenji Hayashihara, Takefumi Saito, Hiroichi Ishikawa, Hideo Ichimura and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Masaharu InagakiDivisions of Thoracic Surgery and Respiratory Medicine, Tsuchiura Kyodo General Hospital and Regional Cancer Center, Tsuchiura, Ibaraki 300-0053, Japan.
Yoko ShinoharaDivisions of Thoracic Surgery and Respiratory Medicine, Tsuchiura Kyodo General Hospital and Regional Cancer Center, Tsuchiura, Ibaraki 300-0053, Japan.
Takayuki KaburagiDivision of Respiratory Medicine, Ibaraki Prefectural Central Hospital and Regional Cancer Center, Kasama, Ibaraki 309-1793, Japan.
Shinsuke HommaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Nobuyuki HizawaDivision of Respiratory Medicine, Faculty of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8576, Japan.
Hiroyuki NakamuraDivisions of Thoracic Surgery and Respiratory Medicine, Tokyo Medical University, Ibaraki Medical Center Hospital, Ami, Ibaraki 300-0395, Japan.
Kenji HayashiharaDivision of Respiratory Medicine, Ibaraki Higashi National Hospital, Tokai, Ibaraki 319-1113, Japan.
Takefumi SaitoDivision of Respiratory Medicine, Ibaraki Higashi National Hospital, Tokai, Ibaraki 319-1113, Japan.
Hiroichi IshikawaDivision of Respiratory Medicine, Tsukuba Medical Center Hospital and Regional Cancer Center, Tsukuba, Ibaraki 305-8558, Japan.
Hideo IchimuraDivisions of Thoracic Surgery and Respiratory Medicine, Hitachi General Hospital, Hitachi, Ibaraki 317-0077, Japan.
Takeshi NawaDivisions of Thoracic Surgery and Respiratory Medicine, Hitachi General Hospital, Hitachi, Ibaraki 317-0077, Japan.
Norihiro KikuchiDivision of Respiratory Medicine, Kasumigaura Medical Center, Tsuchiura, Ibaraki 300-0812, Japan.
Kunihiko MiyazakiDivision of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, Ryugasaki, Ibaraki 301-0854, Japan.
Takahide KodamaDivision of Respiratory Medicine, Ryugasaki Saiseikai General Hospital, Ryugasaki, Ibaraki 301-0854, Japan.
Koichi KamiyamaDivision of Thoracic Surgery, Tsukuba Kinen General Hospital, Tsukuba, Ibaraki 300-2622, Japan.
Hiroaki SatohDivision of Respiratory Medicine, Mito Medical Center, Institute of Clinical Medicine, University of Tsukuba, Mito, Ibaraki 310-0015, Japan.
Kinya FurukawaDivisions of Thoracic Surgery and Respiratory Medicine, Tokyo Medical University, Ibaraki Medical Center Hospital, Ami, Ibaraki 300-0395, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to evaluate the efficacy of erlotinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), in patients undergoing dose reduction and in those with a low body surface area (BSA). The association between dose reduction, low BSA and efficacy, including response rate, disease control rate, time to treatment failure and overall survival, were evaluated in patients prescribed first-line erlotinib for EGFR mutated non-small cell lung cancer patients between April 2012 and March 2015. A total of 22 patients received first-line erlotinib during the study period. A dose reduction of erlotinib for the reason of low BSA and poor performance status occurred in 14 (63.6%) of the patients: 6 (27.3%) had initial dose reduction, 6 (27.3%) had dose reduction in their clinical courses, and 2 (9.1%) had both. Dose reduction of erlotinib with the initial dose of erlotinib/BSA was >80 mg/m

Indexed as

dose reductionerlotinibfirst-linepopulation-basedretrospectivesurvival

Identifiers

PMID26998297
PMCPMC4774513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.